tiprankstipranks
Clene Unveils Phase 3 Trial Design at NEALS
Company Announcements

Clene Unveils Phase 3 Trial Design at NEALS

Don't Miss our Black Friday Offers:

The latest update is out from Clene ( (CLNN) ).

Clene Inc. unveiled the preliminary design for RESTORE-ALS, a significant Phase 3 clinical trial of their CNM-Au8 30 mg treatment, at the 2024 NEALS Meeting. This development marks a pivotal moment in their research efforts, aiming to bring new treatment options for ALS patients. Investors and market enthusiasts may find this an exciting opportunity as the company progresses in its groundbreaking trial.

For detailed information about CLNN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyClene price target lowered to $83 from $86 at Canaccord
TipRanks Auto-Generated NewsdeskClene Announces Q3 2024 Results and ALS Drug Progress
TheFlyClene reports Q3 EPS ($1.22), consensus ($1.32)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App